B. Braun Interventional Systems (BIS) announced today that it is collaborating with Infraredx on a trial for the B. Braun SeQuent Please ReX. Bethlehem, Pa.–based BIS, a B. Braun affiliate, and Infraredx, a Nipro company, will work together to accelerate the FDA investigational device exemption (IDE) clinical trial for the SeQuent Please ReX drug-coated PTCA […]
Nipro (TYO: 8086) subsidiary Infraredx said today that it won expanded FDA 510(k) clearance for its Makoto intravascular imaging system, now cleared to identify patients and coronary plaques at an increased risk of major adverse cardiac events. The approval came based on results from the Lipid-Rich Plaque study in which researchers explored the ability of intravascular […]
Abbott (NYSE:ABT) today released one-year results from a study exploring the use of its Portico transcatheter aortic valve replacement system in patients with symptomatic, severe aortic stenosis, touting low rates of stroke, death and leaks between the valve and native heart tissue. Results from the Portico 1 study were presented during a late-breaking session at the Transcatheter […]
From Esaote launching its new ultrasound device to Nipro’s Infraredx launching in Japan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Esaote launches new ultrasound devices Esaote announced in an Aug. 2 press release that it has launched its new MyLab X7, MyLab X6 and MyLab X5 ultrasound […]
Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]
Nipro (TYO: 8086) said today that it plans to acquire Infraredx and its cardiovascular imaging device for an undisclosed amount. Burlington, Mass.-based Infraredx makes an imaging system that combines intravascular ultrasound and near-infrared spectroscopy to provide images of the interior of coronary blood vessels. The company says the device is designed to detect lipid-core-containing plaque, which it […]
Infraredx last week officially withdrew the planned initial public offering it hoped would raise $56 million, citing "unfavorable market conditions."
Infraredx today set the terms for its forthcoming initial public offering, saying it plans to offer 4 million shares at a range of $13 to $15 each, and set out on a road show to drum up interest from investors.
Infraredx yesterday registered for an initial public offering with the Securities & Exchange Commission, estimating the flotation’s worth at $55 million.
Burlington, Mass.-based Infraredx makes an imaging system that combines intravascular ultrasound and near-infrared spectroscopy to provide images of the interior of coronary blood vessels.
Infraredx touted a study in the Journal of the American College of Cardiology showing its imaging technology could help cardiologists assess a patient’s risk for suffering a heart attack or stroke.